Franklin Biolabs, Inc.

Description: Class 40: Custom manufacturing services for others in the fields of viral-based, non-viral vectors, and vector platforms
Class 42: Research and development relating to production and analysis of viral-based, non-viral vectors, and vector platforms; analytical services being scientific research services in the field of production and analysis of viral-based, non-viral vectors, and vector platforms; development services relation to the quality control services in the fields of viral-based, non-viral vectors, and vector platforms.

Description: Pharmaceutical research services; Pharmaceutical drug development and discovery services, namely, providing translational research tools and services for screening, testing, sequencing, and analysis of DNA- and RNA-encoded genetic material for drug candidate development; cell and gene therapy product development services; Analytical services for drug substance and drug product characterization which are for research use and in accordance with Good Manufacturing Practices (GMP); Preclinical services including pharmacology, pharmacokinetics, and toxicology in well established lab animal models; Research and development and Good Laboratory Practices (GLP) services for bioanalytical testing including immunogenicity, biodistribution and shedding to support pre-clinical (animal) and clinical (human) studies; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing and analytical services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Good Manufacturing Practices (GMP) laboratory and stability testing and analytical services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Providing laboratory services for others in accordance with the Clinical Laboratory Improvement Amendments (CLIA) program; Research and development relating to production and analysis of viral-based vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations for use in medical research for others; Manufacturing services for others in the fields of viral-based and non-viral vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations

Description: Pharmaceutical research services; Pharmaceutical drug development and discovery services, namely, providing translational research tools and services for screening, testing, sequencing, and analysis of DNA- and RNA-encoded genetic material for drug candidate development; cell and gene therapy product development services; Analytical services for drug substance and drug product characterization which are for research use and in accordance with Good Manufacturing Practices (GMP); Preclinical services including pharmacology, pharmacokinetics, and toxicology in well established lab animal models; Research and development and Good Laboratory Practices (GLP) services for bioanalytical testing including immunogenicity, biodistribution and shedding to support pre-clinical (animal) and clinical (human) studies; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing and analytical services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Good Manufacturing Practices (GMP) laboratory and stability testing and analytical services in the fields of therapeutic drug evaluation and development, bioanalytical testing, immunogenicity testing, clinical studies, pre-clinical studies pharmacology, pharmacokinetics, and toxicology; Providing laboratory services for others in accordance with the Clinical Laboratory Improvement Amendments (CLIA) program; Research and development relating to production and analysis of viral-based vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations for use in medical research for others; Manufacturing services for others in the fields of viral-based and non-viral vectors, pharmaceuticals, biologics, vaccines, biotechnological products, and gene and cell therapy preparations